Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLong ChangXSXuliang ShenGJGuorong Jia

Discussion

Loading...

Member takes

Overview

Prospective trial shows improved survival in newly diagnosed multiple myeloma patients with renal impairment, suggesting implications for treatment strategies.

Key Points

  • To assess survival outcomes of pomalidomide/bortezomib/dexamethasone in multiple myeloma patients with renal impairment.
  • Phase 2 clinical trial involving 61 patients with newly diagnosed multiple myeloma and renal impairment
  • Patients received pomalidomide, bortezomib, and dexamethasone for up to 9 cycles
  • Renal response assessed using IMWG criteria, with follow-up analyses performed using Kaplan-Meier methodology.
  • 54.1% of patients completed planned therapy with PVD regimen
  • 3-year progression-free survival rate was 74.4%; 3-year overall survival rate was 80.2%
  • Achieving renal response significantly correlated with improved overall survival.

Cite This Study

Chang et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d13ahttps://doi.org/10.1182/blood-2025-5818
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study2025
  2. 2Survival and clinical response to bortezomib, thalidomide, and dexamethasone in patients with multiple myeloma at a peruvian tertiary care center: A real-world retrospective observational study2025
  3. 3Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance2025
  4. 4Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression2025
  5. 5Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience2025 · 2 citations